Leah Kuntz is the Assistant Managing Editor at Psychiatric Times. She focuses on themes related to medicine and healthcare, particularly in mental health care, psychiatry, and patient care, while also exploring healthcare administration and public health. Leah's work has been featured in Drug Topics, NewsBreak, and Psychiatric Times.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Leah's coverage is heavily focused on the healthcare and pharmaceutical industry, particularly in mental health research. Her articles often cite data and include expert commentary, indicating a preference for evidence-based information from authoritative sources.
Given Leah's focus on mental health topics and reliance on data-driven insights, she would likely be receptive to pitches that offer access to new research findings or interviews with experts who can provide valuable commentary based on empirical evidence. Additionally, she may be interested in exclusive insights regarding innovative treatments or therapeutic approaches related to mental health disorders.
While Leah does not have a specified geographic focus, her coverage appears global in scope as it encompasses advancements and research across various areas of mental health without being limited to specific regions.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Leah Kuntz
A new report shows private practice clinicians deliver over 113 million sessions of mental health care, making up the majority of outpatient care.
By: Leah Kuntz
Massive Lancet meta-analysis suggests most use of antidepressants while pregnant does not raise autism or ADHD risk after confounders, easing treatment decisions.
By: Mark Olfson, Leah Kuntz
Study ties higher schizophrenia rates in Black Americans to neighborhood vulnerability, spotlighting faster early-psychosis care and social supports.
By: Leah Kuntz
Real-world registry data reveals young adults with mood disorders face high TD burden yet low diagnosis rates, spotlighting urgent screening gaps.
By: Leah Kuntz
Synendos launches a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety symptoms with improved safety and adherence.
By: Leah Kuntz
New Surgeon General advisory warns of youth screen and social media harms, urging families, schools, and clinicians to act with the 5 Ds.
By: Leah Kuntz
FDA clears Modius Spero headset, a noninvasive at-home neuromodulation therapy that eases PTSD symptoms, with veterans first to access via VA.
By: Guy Goodwin, Leah Kuntz
Phase 3 data show COMP360 psilocybin rapidly lifts treatment-resistant depression, with durable MADRS gains and stronger effects from two sessions.
Explore Pride Month insights on LGBTQ+ and other minoritized patients—social determinants, research, practice tips, and case studies for clinicians, in our June theme.
By: Leah Kuntz
Phase 2 trial shows elunetirom rapidly eases bipolar depression symptoms with strong response, good tolerability, and FDA Fast Track momentum.
